Leaving GSK Pro

You are leaving GSK Pro to visit a separate website not associated with GSK Pro, a portal for US Healthcare Professionals.There are website links to third-party sites on GSK Pro. GSK is not responsible for content on third-party websites.




For the last 3 years, the GOLD report has recommended starting symptomatic patients on a LAMA/LABA.

Adverse Reactions

The GOLD 2019 Report

  • Continues to emphasize the role of LAMA/LABA for patients with COPD1
  • Does not include ICS/LABA as initial treatment in many patients1

ANORO was studied in patients with moderate or worse COPD.


For patients whose COPD is not controlled by a LAMA/LABA, GOLD recommends triple therapy.


ANORO is for the once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

ANORO is NOT for the relief of acute bronchospasm or for asthma.

Start with ANORO for your symptomatic patients with COPD

Adverse Reactions

Hypothetical patient story.

Frank, age 58, professor, is a symptomatic patient with moderate COPD not yet on maintenance therapy and has had no exacerbations in the last 12 months. He is currently experiencing:

  • Wheezing
  • Cough
  • Shortness of breath leading to:
        — Regular rescue medication use
        — Pulling away from normal activities


ANORO is not indicated to reduce COPD exacerbations.

In GSK pivotal studies for ANORO, an exacerbation was defined as acute worsening of symptoms of COPD requiring the use of any treatment beyond study drug or rescue albuterol, including2:

  • Use of antibiotics and/or systemic corticosteroids and/or
  • Emergency treatment or hospitalization

References: 1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2019 report. www.goldcopd.org. Accessed November 27, 2018. 2. Data on file, GSK.